Cholesterol Lowering Drug (Jupiter) Trial Shenanigans


Wow.  I really think if most of the American public knew the real story of what goes behind some of these trials we’d all be sickened.  In it’s essence, the Jupiter trial looked at the prevention of heart disease in patients who had NORMAL cholesterol, but elevated inflammation.  Essential understanding that the “cholesterol blame game” was going away and they needed to find a new lab value that they could use the drug for.

The study was stopped early and declared a rousing success.  Much fanfare was heard and the medical journals and editorials sung it’s praise.  Oops.  A little too soon.  A closer look at the data raises some serious suspicions.  Basically, the trial was stopped early when predetermined events occurred just 2 yrs into the trial.

Furthermore, when you look at a population, certain statistics are expected.  Here’s the quick details:

  • The study found that statin drugs did NOT protect against deaths from heart attack and stroke.
  • In the general population, cardiovascular deaths account for about 40% of the total number of deaths.  Of these heart attacks, around 50% of these are fatal.

But in the Jupiter trial?  Apparently miracles occurred.  Cardiovascular mortality accounted for under 20% (instead of 50%) of the deaths, and the fatality rate of these heart attacks was very low (instead of the expected 50%).  This raises serious questions about the validity of the data and suggests that funding of the trial may have had a strong influence on the interpretation of the data.

Read More

James Bogash

For more than a decade, Dr. Bogash has stayed current with the medical literature as it relates to physiology, disease prevention and disease management. He uses his knowledge to educate patients, the community and cyberspace on the best way to avoid and / or manage chronic diseases using lifestyle and targeted supplementation.